Mylan Misled Investors Over EpiPen Pricing Probe, SEC Says

(Bloomberg) -- Mylan NV misled investors for at least a year about a Justice Department investigation into the allergy shot EpiPen that would eventually cost the company nearly $500 million, the U....
BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.